cycD1/CCND1 Cancer Research Results

cycD1/CCND1, cyclin D1 pathway: Click to Expand ⟱
Source:
Type:
Also called CCND1 Gatekeeper of Cell-Cycle Commitment
The main function of cyclin D1 is to maintain cell cycle and to promote cell proliferation. Cyclin D1 is a key regulatory protein involved in the cell cycle, particularly in the transition from the G1 phase to the S phase. It is part of the cyclin-dependent kinase (CDK) complex, where it binds to CDK4 or CDK6 to promote cell cycle progression.
Cyclin D1 is crucial for the regulation of the cell cycle. Overexpression or dysregulation of cyclin D1 can lead to uncontrolled cell proliferation, a hallmark of cancer.
Cyclin D1 is often found to be overexpressed in various cancers.
Cyclin D1 can interact with tumor suppressor proteins, such as retinoblastoma (Rb). When cyclin D1 is overexpressed, it can lead to the phosphorylation and inactivation of Rb, releasing E2F transcription factors that promote the expression of genes required for DNA synthesis and cell cycle progression.
Cyclin D1 is influenced by various signaling pathways, including the PI3K/Akt and MAPK pathways, which are often activated in cancer.
In some cancers, high levels of cyclin D1 expression have been associated with poor prognosis, making it a potential biomarker for cancer progression and treatment response.
NA, Not Available: Click to Expand ⟱
none (reserved)
Scientific Papers found: Click to Expand⟱
1334- AG,    Astragalus membranaceus: A Review of Its Antitumor Effects on Non-Small Cell Lung Cancer
- Review, NA, NA
TumCP↓, Apoptosis↑, NF-kB↓, p50↓, cycD1/CCND1↓, Bcl-xL↓, ChemoSen↑, angioG↓, ChemoSen↑,
556- ART/DHA,    Artemisinins as a novel anti-cancer therapy: Targeting a global cancer pandemic through drug repurposing
- Review, NA, NA
IL6↓, IL1↓, TNF-α↓, TGF-β↓, NF-kB↓, MIP2↓, PGE2↓, NO↓, Hif1a↓, KDR/FLK-1↓, VEGF↓, MMP2↓, TIMP2↑, ITGB1↑, NCAM↑, p‑ATM↑, p‑ATR↑, p‑CHK1↑, p‑Chk2↑, Wnt/(β-catenin)↓, PI3K↓, Akt↓, ERK↓, cMyc↓, mTOR↓, survivin↓, cMET↓, EGFR↓, cycD1/CCND1↓, cycE1↓, CDK4/6↓, p16↑, p27↑, Apoptosis↑, TumAuto↑, Ferroptosis↑, oncosis↑, TumCCA↑, ROS↑, DNAdam↑, RAD51↓, HR↓,
564- ART/DHA,  Cisplatin,    Dihydroartemisinin as a Putative STAT3 Inhibitor, Suppresses the Growth of Head and Neck Squamous Cell Carcinoma by Targeting Jak2/STAT3 Signaling
- in-vitro, NA, HN30
JAK2↓, STAT3↓, MMP2↓, MMP9↓, Mcl-1↓, Bcl-xL↓, cycD1/CCND1↓, VEGF↓, TumCCA↑, ChemoSen↑,
2335- BBR,    Chemoproteomics reveals berberine directly binds to PKM2 to inhibit the progression of colorectal cancer
- in-vitro, CRC, HT29 - in-vitro, CRC, HCT116 - in-vivo, NA, NA
PKM2↓, Glycolysis↓, p‑STAT3↓, Bcl-2↓, cycD1/CCND1↓, TumCG↓, Ki-67↓, lactateProd↓, glucose↓,
2745- BetA,    Betulinic acid inhibits colon cancer cell and tumor growth and induces proteasome-dependent and -independent downregulation of specificity proteins (Sp) transcription factors
- in-vitro, CRC, RKO - in-vitro, CRC, SW480 - in-vivo, NA, NA
Apoptosis↑, TumCG↓, Sp1/3/4↓, survivin↓, VEGF↓, p65↓, EGFR↓, cycD1/CCND1↓, ROS↑, MMP↓,
1422- Bos,    Boswellic acid exerts antitumor effects in colorectal cancer cells by modulating expression of the let-7 and miR-200 microRNA family
- in-vitro, CRC, NA - in-vivo, NA, NA
5LO↓, TumCG↓, Let-7↑, miR-200b↑, NF-kB↓, cMyc↓, cycD1/CCND1↓, MMP9↓, CXCR4↓, VEGF↓, Bcl-xL↓, survivin↓, IAP1↓, XIAP↓, TumCG↓, CDK6↓, Vim↓, E-cadherin↑,
1230- CA,  Caff,    Caffeine and Caffeic Acid Inhibit Growth and Modify Estrogen Receptor and Insulin-like Growth Factor I Receptor Levels in Human Breast Cancer
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231 - Human, NA, NA
TumVol↓, TumCG↓, ER(estro)↓, cycD1/CCND1↓, IGF-1R↓, p‑Akt↓,
1260- CAP,    Capsaicin inhibits in vitro and in vivo angiogenesis
- vitro+vivo, NA, NA
VEGF↓, angioG↓, TumCCA↑, cycD1/CCND1↓, Akt↓,
1232- Gra,    Graviola: A Systematic Review on Its Anticancer Properties
- Review, NA, NA
EGFR↓, cycD1/CCND1↓, Bcl-2↓, TumCCA↑, Apoptosis↑, ROS↑, MMP↓, BAX↑, Cyt‑c↑, Hif1a↓, NF-kB↓, GLUT1↓, GLUT4↓, HK2↓, LDHA↓, ATP↓,
2865- HNK,    Liposomal Honokiol induces ROS-mediated apoptosis via regulation of ERK/p38-MAPK signaling and autophagic inhibition in human medulloblastoma
- in-vitro, MB, DAOY - vitro+vivo, NA, NA
BioAv↓, BioAv↓, TumCP↓, selectivity↑, P53↑, P21↑, CDK4↓, cycD1/CCND1↓, mtDam↑, ROS↑, eff↓, Casp3↑, BAX↑, LC3II↑, Beclin-1↑, ATG7↑, p62↑, eff↑, ChemoSen↑, *toxicity↓,
1167- IVM,    The river blindness drug Ivermectin and related macrocyclic lactones inhibit WNT-TCF pathway responses in human cancer
- vitro+vivo, NA, NA
Wnt↓, TCF↓, TumCP↓, Apoptosis↑, β-catenin/ZEB1↓, cycD1/CCND1↓,
1141- Myr,    Myricetin: targeting signaling networks in cancer and its implication in chemotherapy
- Review, NA, NA
*PI3K↑, *Akt↑, p‑Akt↓, SIRT3↑, p‑ERK↓, p38↓, VEGF↓, MEK↓, MKK4↓, MMP9↓, Raf↓, F-actin↓, MMP2↓, COX2↓, BMP2↓, cycD1/CCND1↓, Bax:Bcl2↑, EMT↓, EGFR↓, TumAuto↑,
1805- NarG,    Naringenin suppresses epithelial ovarian cancer by inhibiting proliferation and modulating gut microbiota
- in-vitro, Ovarian, A2780S - in-vivo, NA, NA
TumCP↓, TumCMig↓, PI3K↓, TumVol↓, TumW↓, BioAv↑, GutMicro↑, Dose∅, eff↑, EGFR↓, cycD1/CCND1↓, toxicity∅,
1938- PL,    Piperlongumine regulates epigenetic modulation and alleviates psoriasis-like skin inflammation via inhibition of hyperproliferation and inflammation
- Study, PSA, NA - in-vivo, NA, NA
ROS↑, Apoptosis↑, MMP↓, TumCCA↑, DNAdam↑, STAT3↓, Akt↓, PCNA↓, Ki-67↓, cycD1/CCND1↓, Bcl-2↓, K17↓, HDAC↓, ROS↑, *IL1β↓, *IL6↓, *TNF-α↓, *IL17↓, *IL22↓,
58- QC,  doxoR,    Quercetin induces cell cycle arrest and apoptosis in CD133+ cancer stem cells of human colorectal HT29 cancer cell line and enhances anticancer effects of doxorubicin
- in-vitro, CRC, HT-29 - in-vitro, NA, CD133+
Bcl-2↓, TumCCA↑, CD133↓, CSCs↓, ChemoSen↑, CycB/CCNB1↑, cycE/CCNE↓, cycD1/CCND1↓, E2Fs↓,
53- QC,    Quercetin regulates β-catenin signaling and reduces the migration of triple negative breast cancer
- in-vitro, BC, MDA-MB-231 - NA, NA, MDA-MB-468
E-cadherin↑, Vim↓, cycD1/CCND1↓, cMyc↓, EMT↓, TumCG↓, TumCMig↓, β-catenin/ZEB1↓, ChemoSen↑,
978- SIL,    A comprehensive evaluation of the therapeutic potential of silibinin: a ray of hope in cancer treatment
- Review, NA, NA
PI3K↓, Akt↓, NF-kB↓, Wnt/(β-catenin)↓, MAPK↓, TumCP↓, TumCCA↑, Apoptosis↑, p‑EGFR↓, JAK2↓, STAT5↓, cycD1/CCND1↓, hTERT/TERT↓, AP-1↓, MMP9↓, miR-21↓, miR-155↓, Casp9↑, BID↑, ERK↓, Akt2↓, DNMT1↓, P53↑, survivin↓, Casp3↑, ROS↑,
2230- SK,    Shikonin induces ROS-based mitochondria-mediated apoptosis in colon cancer
- in-vitro, CRC, HCT116 - in-vivo, NA, NA
TumCG↓, Bcl-2↓, ROS↑, Bcl-xL↓, MMP↓, Casp↑, selectivity↑, cycD1/CCND1↓, TumCCA↑, eff↓,
2194- SK,    Efficacy of Shikonin against Esophageal Cancer Cells and its possible mechanisms in vitro and in vivo
- in-vitro, ESCC, Eca109 - in-vitro, ESCC, EC9706 - in-vivo, NA, NA
tumCV↓, TumCCA↑, Apoptosis↑, EGFR↓, PI3K↓, Hif1a↓, PKM2↓, cycD1/CCND1↓, AntiTum↑,
2083- TQ,    Thymoquinone inhibits proliferation in gastric cancer via the STAT3 pathway in vivo and in vitro
- in-vitro, GC, HGC27 - in-vitro, GC, BGC-823 - in-vitro, GC, SGC-7901 - in-vivo, NA, NA
p‑STAT3↓, JAK2↓, c-Src↓, Bcl-2↓, cycD1/CCND1↓, survivin↓, VEGF↓, Casp3?, Casp7?, Casp9?, *toxicity∅, TumVol↓,
3412- TQ,    Thymoquinone induces oxidative stress-mediated apoptosis through downregulation of Jak2/STAT3 signaling pathway in human melanoma cells
- in-vitro, Melanoma, SK-MEL-28 - in-vivo, NA, NA
Apoptosis↑, JAK2↓, STAT3↓, cycD1/CCND1↓, survivin↓, ROS↑, eff↓,
3429- TQ,    Thymoquinone exerts potent growth-suppressive activity on leukemia through DNA hypermethylation reversal in leukemia cells
- in-vitro, AML, NA - in-vivo, NA, NA
DNMT1↓, Sp1/3/4↓, NF-kB↓, Apoptosis↑, Casp↑, Bcl-xL↓, COX2↓, iNOS↓, 5LO↓, TNF-α↓, cycD1/CCND1↓, BioAv↝, TumCG↓,

Showing Research Papers: 1 to 22 of 22

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 22

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

Ferroptosis↑, 1,   ROS↑, 9,   SIRT3↑, 1,  

Mitochondria & Bioenergetics ⓘ

ATP↓, 1,   MEK↓, 1,   MKK4↓, 1,   MMP↓, 4,   mtDam↑, 1,   Raf↓, 1,   XIAP↓, 1,  

Core Metabolism/Glycolysis ⓘ

ATG7↑, 1,   cMyc↓, 3,   glucose↓, 1,   Glycolysis↓, 1,   HK2↓, 1,   lactateProd↓, 1,   LDHA↓, 1,   PKM2↓, 2,  

Cell Death ⓘ

Akt↓, 4,   p‑Akt↓, 2,   Apoptosis↑, 10,   BAX↑, 2,   Bax:Bcl2↑, 1,   Bcl-2↓, 6,   Bcl-xL↓, 5,   BID↑, 1,   BMP2↓, 1,   Casp↑, 2,   Casp3?, 1,   Casp3↑, 2,   Casp7?, 1,   Casp9?, 1,   Casp9↑, 1,   p‑Chk2↑, 1,   Cyt‑c↑, 1,   Ferroptosis↑, 1,   hTERT/TERT↓, 1,   IAP1↓, 1,   iNOS↓, 1,   MAPK↓, 1,   Mcl-1↓, 1,   oncosis↑, 1,   p27↑, 1,   p38↓, 1,   survivin↓, 6,  

Kinase & Signal Transduction ⓘ

Sp1/3/4↓, 2,  

Transcription & Epigenetics ⓘ

miR-21↓, 1,   tumCV↓, 1,  

Autophagy & Lysosomes ⓘ

Beclin-1↑, 1,   LC3II↑, 1,   p62↑, 1,   TumAuto↑, 2,  

DNA Damage & Repair ⓘ

p‑ATM↑, 1,   p‑ATR↑, 1,   p‑CHK1↑, 1,   DNAdam↑, 2,   DNMT1↓, 2,   HR↓, 1,   p16↑, 1,   P53↑, 2,   PCNA↓, 1,   RAD51↓, 1,  

Cell Cycle & Senescence ⓘ

CDK4↓, 1,   CycB/CCNB1↑, 1,   cycD1/CCND1↓, 22,   cycE/CCNE↓, 1,   cycE1↓, 1,   E2Fs↓, 1,   P21↑, 1,   TumCCA↑, 9,  

Proliferation, Differentiation & Cell State ⓘ

CD133↓, 1,   cMET↓, 1,   CSCs↓, 1,   EMT↓, 2,   ERK↓, 2,   p‑ERK↓, 1,   HDAC↓, 1,   IGF-1R↓, 1,   Let-7↑, 1,   mTOR↓, 1,   PI3K↓, 4,   c-Src↓, 1,   STAT3↓, 3,   p‑STAT3↓, 2,   STAT5↓, 1,   TCF↓, 1,   TumCG↓, 8,   Wnt↓, 1,   Wnt/(β-catenin)↓, 2,  

Migration ⓘ

5LO↓, 2,   Akt2↓, 1,   AP-1↓, 1,   CDK4/6↓, 1,   E-cadherin↑, 2,   F-actin↓, 1,   ITGB1↑, 1,   Ki-67↓, 2,   miR-155↓, 1,   miR-200b↑, 1,   MMP2↓, 3,   MMP9↓, 4,   NCAM↑, 1,   TGF-β↓, 1,   TIMP2↑, 1,   TumCMig↓, 2,   TumCP↓, 5,   Vim↓, 2,   β-catenin/ZEB1↓, 2,  

Angiogenesis & Vasculature ⓘ

angioG↓, 2,   EGFR↓, 6,   p‑EGFR↓, 1,   Hif1a↓, 3,   KDR/FLK-1↓, 1,   NO↓, 1,   VEGF↓, 7,  

Barriers & Transport ⓘ

GLUT1↓, 1,   GLUT4↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 2,   CXCR4↓, 1,   IL1↓, 1,   IL6↓, 1,   JAK2↓, 4,   MIP2↓, 1,   NF-kB↓, 6,   p50↓, 1,   p65↓, 1,   PGE2↓, 1,   TNF-α↓, 2,  

Hormonal & Nuclear Receptors ⓘ

CDK6↓, 1,   ER(estro)↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 2,   BioAv↑, 1,   BioAv↝, 1,   ChemoSen↑, 6,   Dose∅, 1,   eff↓, 3,   eff↑, 2,   selectivity↑, 2,  

Clinical Biomarkers ⓘ

EGFR↓, 6,   p‑EGFR↓, 1,   GutMicro↑, 1,   hTERT/TERT↓, 1,   IL6↓, 1,   Ki-67↓, 2,  

Functional Outcomes ⓘ

AntiTum↑, 1,   K17↓, 1,   toxicity∅, 1,   TumVol↓, 3,   TumW↓, 1,  
Total Targets: 149

Pathway results for Effect on Normal Cells:


Cell Death ⓘ

Akt↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

PI3K↑, 1,  

Immune & Inflammatory Signaling ⓘ

IL17↓, 1,   IL1β↓, 1,   IL22↓, 1,   IL6↓, 1,   TNF-α↓, 1,  

Clinical Biomarkers ⓘ

IL6↓, 1,  

Functional Outcomes ⓘ

toxicity↓, 1,   toxicity∅, 1,  
Total Targets: 10

Scientific Paper Hit Count for: cycD1/CCND1, cyclin D1 pathway
3 Thymoquinone
2 Artemisinin
2 Quercetin
2 Shikonin
1 Astragalus
1 Cisplatin
1 Berberine
1 Betulinic acid
1 Boswellia (frankincense)
1 Caffeic acid
1 Caffeine
1 Capsaicin
1 Graviola
1 Honokiol
1 Ivermectin
1 Myricetin
1 Naringin
1 Piperlongumine
1 doxorubicin
1 Silymarin (Milk Thistle) silibinin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:0  Cells:%  prod#:%  Target#:73  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page